Takeda Pharmaceutical (TSE:4502) Wins FDA Approval For ORZEYFUL, Is The Stock Still Cheap?
Takeda Pharmaceutical (TSE:4502) is back in focus after the U.S. Food and Drug Administration approved ORZEYFUL, a first in class oral orexin receptor agonist for adults with narcolepsy type 1.
See our latest analysis for Takeda Pharmaceutical.
The FDA approval of ORZEYFUL has arrived alongside building momentum in Takeda Pharmaceutical's stock, with a 1 day share price return of 3.43% and a year to date share price return of 15.99%. The 1 year total shareholder return of 31.54% points to gains that have compounded over a longer horizon.
If this kind of healthcare breakthrough has your attention, it could be a good moment to scan other companies at the intersection of medicine and AI by checking out 7 healthcare AI stocks
Takeda Pharmaceutical’s strong run after the ORZEYFUL approval leaves you weighing two options: step in after this jump or wait and see if enthusiasm cools. The valuation numbers help frame that choice next.
Most Popular Narrative: 9% Undervalued
The most followed narrative puts Takeda Pharmaceutical’s fair value at ¥6,262.69, which sits above the last close of ¥5,702. This gap frames ORZEYFUL’s approval inside a broader earnings recovery story rather than a one day reaction.
The anticipated moderation and eventual stabilization of VYVANSE generic erosion after FY2025 will remove a major headwind for revenues, allowing Takeda's core growth and launch products to drive top line and earnings recovery going forward.
Analysts are building this fair value on a shift from losses to positive earnings, modest revenue growth and a richer profit margin profile. Curious which assumptions carry the most weight.
Result: Fair Value of ¥6,262.69 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Takeda Pharmaceutical narrative could be challenged if generic and biosimilar competition bites harder than expected, or if key late stage pipeline trials underperform.
Find out about the key risks to this Takeda Pharmaceutical narrative.
Next Steps
With both risks and rewards in play for Takeda Pharmaceutical, this is a moment to look closely at the data and decide quickly where you stand. To weigh both sides in one place, take a closer look at the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Takeda Pharmaceutical?
Do not stop with Takeda Pharmaceutical. Broaden your watchlist with other clear opportunities that fit your style so you are not relying on a single story.
- Target dependable income streams by reviewing 34 dividend fortresses and see which companies currently offer higher yields with a focus on resilience.
- Hunt for quality at a sensible price by scanning 27 high quality undervalued stocks to spot companies where fundamentals and valuation still look aligned.
- Prioritise sleep at night holdings with 60 resilient stocks with low risk scores and see which businesses score well on financial strength and stability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com